https://www.brighteon.com/3fad7413-9369-4fe7-b61c-cdd55616f270 Ivermectin Not approved by the FDA and not recommended by the Panel for the treatment of COVID-19. Currently under investigation in clinical trials. Dose for COVID-19 in Clinical Trials: IVM 200–600 μg/kg PO as a single dose or a once-daily dose for up to 5 days Dizziness Pruritis GI effects (e.g., nausea, diarrhea) Neurological AEs have been reported when IVM has been used to treat parasitic diseases, but it is not clear whether these AEs were caused by IVM or the underlying conditions. Monitor for potential AEs. Minor CYP3A4 substrate P-gp substrate Generally given on an empty stomach with water; however, administering IVM with food increases its bioavailability. 4 A list of clinical trials is available: Ivermectin Es wurde am Menschen getestet und hat auch wegen dem Menschen den Nobelpreis bekommen! Es ist am Tier und am Menschen getestet worden. https://www.covid19treatmentguidelines.nih.go